The same observation was also highlighted in EGFR-mutated NSCLC patients by Jin et al., who found that TP53 had the higher co-mutation rate with respect to other genic alterations (72.5%), but showed no associations with survival [121]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.